Inhalation Sciences to present FDA-funded DissolvIt evaluation results at respiratory drug development conferences
PUBT · 2d ago
Share
Listen to the news
- Inhalation Sciences will present results from an FDA-funded evaluation of DissolvIt at three conferences in August–October 2026.
- Poster presentation scheduled for the Rapid Response Partnership Vehicle General Membership Meeting in Arlington, Maryland, Aug. 26–27, 2026.
- Poster presentation planned for the Inhaled & Nasal Biologics I DNA Forum in Cambridge, UK, Sept. 24–25, 2026.
- Podium presentation slated for the MVIC Symposium in Lund, Sweden, Oct. 21–22, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200230BITN____UKPR__EN_20260819-BIT-9742-0) on August 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending